Cargando…

Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients—Real-World Data From Hungary

Pomalidomide is a third generation immunomodulatory drug in the treatment of refractory and relapsed multiple myeloma patients. Our aim was to investigate the efficacy and safety of pomalidomide therapy in a real world setting. Eighty-six Hungarian patients were included, 45 of whom received pomalid...

Descripción completa

Detalles Bibliográficos
Autores principales: Lovas, Szilvia, Obajed Al-Ali, Nóra, Varga, Gergely, Szita, Virág, Alizadeh, Hussain, Plander, Márk, Rajnics, Péter, Illés, Árpád, Szemlaky, Zsuzsa, Mikala, Gábor, Váróczy, László
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9573944/
https://www.ncbi.nlm.nih.gov/pubmed/36262875
http://dx.doi.org/10.3389/pore.2022.1610645
_version_ 1784810989932249088
author Lovas, Szilvia
Obajed Al-Ali, Nóra
Varga, Gergely
Szita, Virág
Alizadeh, Hussain
Plander, Márk
Rajnics, Péter
Illés, Árpád
Szemlaky, Zsuzsa
Mikala, Gábor
Váróczy, László
author_facet Lovas, Szilvia
Obajed Al-Ali, Nóra
Varga, Gergely
Szita, Virág
Alizadeh, Hussain
Plander, Márk
Rajnics, Péter
Illés, Árpád
Szemlaky, Zsuzsa
Mikala, Gábor
Váróczy, László
author_sort Lovas, Szilvia
collection PubMed
description Pomalidomide is a third generation immunomodulatory drug in the treatment of refractory and relapsed multiple myeloma patients. Our aim was to investigate the efficacy and safety of pomalidomide therapy in a real world setting. Eighty-six Hungarian patients were included, 45 of whom received pomalidomide ± an alkylating agent, while in 38 of them pomalidomide was combined with a proteasome inhibitor. 56 patients (65%) showed any response to the treatment with 18 complete or very good partial remissions and 38 partial remissions. At a median duration of follow-up of 18.6 months, the median progression-free survival (PFS) was 9.03 months, while the median overall survival (OS) was 16.53 months in the whole cohort. Patients with early stage disease (R-ISS 1 and 2) had better survival results than those with stage 3 myeloma (p = 0.002). Neither the number of prior treatment lines, nor lenalidomide refractoriness had a significant impact on PFS. PFS was found similar between the cohort of patients with impaired renal function and the cohort without kidney involvement. During the study, eight mortal infections and two fatal bleeding complications occurred, however, mild hematologic and gastrointestinal toxicities were identified as the most frequent adverse events. The results of our investigations confirm that pomalidomide is an effective treatment option for relapsed/refractory MM, besides, the safety profile is satisfactory in subjects with both normal and impaired renal function.
format Online
Article
Text
id pubmed-9573944
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95739442022-10-18 Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients—Real-World Data From Hungary Lovas, Szilvia Obajed Al-Ali, Nóra Varga, Gergely Szita, Virág Alizadeh, Hussain Plander, Márk Rajnics, Péter Illés, Árpád Szemlaky, Zsuzsa Mikala, Gábor Váróczy, László Pathol Oncol Res Pathology and Oncology Archive Pomalidomide is a third generation immunomodulatory drug in the treatment of refractory and relapsed multiple myeloma patients. Our aim was to investigate the efficacy and safety of pomalidomide therapy in a real world setting. Eighty-six Hungarian patients were included, 45 of whom received pomalidomide ± an alkylating agent, while in 38 of them pomalidomide was combined with a proteasome inhibitor. 56 patients (65%) showed any response to the treatment with 18 complete or very good partial remissions and 38 partial remissions. At a median duration of follow-up of 18.6 months, the median progression-free survival (PFS) was 9.03 months, while the median overall survival (OS) was 16.53 months in the whole cohort. Patients with early stage disease (R-ISS 1 and 2) had better survival results than those with stage 3 myeloma (p = 0.002). Neither the number of prior treatment lines, nor lenalidomide refractoriness had a significant impact on PFS. PFS was found similar between the cohort of patients with impaired renal function and the cohort without kidney involvement. During the study, eight mortal infections and two fatal bleeding complications occurred, however, mild hematologic and gastrointestinal toxicities were identified as the most frequent adverse events. The results of our investigations confirm that pomalidomide is an effective treatment option for relapsed/refractory MM, besides, the safety profile is satisfactory in subjects with both normal and impaired renal function. Frontiers Media S.A. 2022-10-03 /pmc/articles/PMC9573944/ /pubmed/36262875 http://dx.doi.org/10.3389/pore.2022.1610645 Text en Copyright © 2022 Lovas, Obajed Al-Ali, Varga, Szita, Alizadeh, Plander, Rajnics, Illés, Szemlaky, Mikala and Váróczy. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pathology and Oncology Archive
Lovas, Szilvia
Obajed Al-Ali, Nóra
Varga, Gergely
Szita, Virág
Alizadeh, Hussain
Plander, Márk
Rajnics, Péter
Illés, Árpád
Szemlaky, Zsuzsa
Mikala, Gábor
Váróczy, László
Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients—Real-World Data From Hungary
title Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients—Real-World Data From Hungary
title_full Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients—Real-World Data From Hungary
title_fullStr Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients—Real-World Data From Hungary
title_full_unstemmed Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients—Real-World Data From Hungary
title_short Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients—Real-World Data From Hungary
title_sort pomalidomide treatment in relapsed/refractory multiple myeloma patients—real-world data from hungary
topic Pathology and Oncology Archive
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9573944/
https://www.ncbi.nlm.nih.gov/pubmed/36262875
http://dx.doi.org/10.3389/pore.2022.1610645
work_keys_str_mv AT lovasszilvia pomalidomidetreatmentinrelapsedrefractorymultiplemyelomapatientsrealworlddatafromhungary
AT obajedalalinora pomalidomidetreatmentinrelapsedrefractorymultiplemyelomapatientsrealworlddatafromhungary
AT vargagergely pomalidomidetreatmentinrelapsedrefractorymultiplemyelomapatientsrealworlddatafromhungary
AT szitavirag pomalidomidetreatmentinrelapsedrefractorymultiplemyelomapatientsrealworlddatafromhungary
AT alizadehhussain pomalidomidetreatmentinrelapsedrefractorymultiplemyelomapatientsrealworlddatafromhungary
AT plandermark pomalidomidetreatmentinrelapsedrefractorymultiplemyelomapatientsrealworlddatafromhungary
AT rajnicspeter pomalidomidetreatmentinrelapsedrefractorymultiplemyelomapatientsrealworlddatafromhungary
AT illesarpad pomalidomidetreatmentinrelapsedrefractorymultiplemyelomapatientsrealworlddatafromhungary
AT szemlakyzsuzsa pomalidomidetreatmentinrelapsedrefractorymultiplemyelomapatientsrealworlddatafromhungary
AT mikalagabor pomalidomidetreatmentinrelapsedrefractorymultiplemyelomapatientsrealworlddatafromhungary
AT varoczylaszlo pomalidomidetreatmentinrelapsedrefractorymultiplemyelomapatientsrealworlddatafromhungary